Who holds the memantine patents and what are they for?
Memantine is a generic drug in most markets, so patent coverage is usually about specific product versions, formulations (like extended-release tablets), or particular uses in combination/therapeutic areas rather than the base “memantine itself,” which is already long off-patent in many jurisdictions. Patent rights for memantine commonly involve specific filings and national/regional grants that can differ by country and dosage form.
When did the original memantine patent expire?
Because patent expirations depend on the country and the specific patent family (and whether patents were extended), the exact expiration date varies by jurisdiction. In practice, memantine has been available generically for years, which indicates the core compound patent protection has expired in major markets.
Can memantine generics enter before patents expire?
Generics typically cannot market until relevant patent protections for the specific product/label/dosage form have expired or been cleared. Even after the main compound patent expires, follow-on protections (like formulation, process, or controlled-release patents) can delay entry for particular versions.
Are there still active memantine patents today?
Some memantine-related patents may still be active in specific countries or for specific versions (for example, particular formulations or combinations). Whether any given patent is currently active depends on the patent number, the jurisdiction, and the maintenance/expiry status.
How do you check a specific memantine patent’s status?
To determine whether a particular memantine patent is active or expired, you generally need:
- the patent/publication number, and
- the jurisdiction (US, EP/EU, UK, etc.),
then check official sources (for example, national patent registers and major patent databases) for expiry dates and legal status.
What’s different between memantine and combination patents (memantine + donepezil)?
Combo products can have their own patent families covering the fixed-dose combination, the specific dosing regimen, and sometimes manufacturing/film-coating or other formulation details. These combination patents may have different expiry timelines than memantine alone.
Why do search results show different memantine patent dates?
Different dates show up because patent families publish over time, priority dates differ from grant dates, and expirations differ by country. Also, litigation or patent adjustments can affect when generic approval/launch happens even after a compound patent expires.
What information would let you get an exact answer?
If you share either:
- the country/jurisdiction you care about (US, EU/EP, UK, etc.), and
- the patent number (or the product name/dosage form, like “memantine extended-release 28 mg”),
I can narrow the answer to the specific memantine patent(s) and their likely expiry/remaining coverage.
Sources: None provided.